To extend the benefits of CDK4/6 inhibition and to mitigate acquired resistance in cancer management, the adaptations of cancer cells to CDK4/6 inhibition need to be investigated by exploring not only altered signaling pathways but also their crosstalk with metabolic reprogramming. The gene discussed is CDK4; the disease is cancer.